{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:42:21Z","timestamp":1780656141229,"version":"3.54.1"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Fabry disease (FD) is an X-linked disorder of glycosphingolipid metabolism caused by mutations in the GLA gene encoding alpha-galactosidase A (\u03b1-Gal). Loss of \u03b1-Gal activity leads to progressive lysosomal accumulation of \u03b1-Gal substrate, predominately globotriaosylceramide (Gb3) and its deacylated derivative globotriaosylsphingosine (lyso\u2010Gb3). FD manifestations include early onset neuropathic pain, gastrointestinal symptoms, and later onset life-threatening renal, cardiovascular and cerebrovascular disorders. Current treatments can preserve kidney function but are not very effective in preventing progression of cardiovascular pathology which remains the most common cause of premature death in FD patients. There is a significant need for a translational model that could be used for testing cardiac efficacy of new drugs. Two mouse models of FD have been developed. The \u03b1-Gal A-knockout (<jats:italic>Gla<\/jats:italic>KO) model is characterized by progressive tissue accumulation of Gb3 and lyso-Gb3 but does not develop any Fabry pathology besides mild peripheral neuropathy. Reports of minor cardiac function abnormalities in <jats:italic>Gla<\/jats:italic>KO model are inconsistent between different studies. Recently, G3Stg\/<jats:italic>Gla<\/jats:italic>KO was generated by crossbreeding <jats:italic>Gla<\/jats:italic>KO with transgenic mice expressing human Gb3 synthase. G3Stg\/<jats:italic>Gla<\/jats:italic>KO demonstrate higher tissue substrate accumulation and develop cellular and tissue pathologies. Functional renal pathology analogous to that found in early stages of FD has also been described in this model. The objective of this study is to characterize cardiac phenotype in <jats:italic>Gla<\/jats:italic>KO and G3Stg\/<jats:italic>Gla<\/jats:italic>KO mice using echocardiography. Longitudinal assessments of cardiac wall thickness, mass and function were performed in <jats:italic>Gla<\/jats:italic>KO and wild-type (WT) littermate controls from 5\u201313 months of age. G3Stg\/<jats:italic>Gla<\/jats:italic>KO and WT mice were assessed between 27\u201328 weeks of age due to their shortened lifespan. Several cardiomyopathy characteristics of early Fabry pathology were found in <jats:italic>Gla<\/jats:italic>KO mice, including mild cardiomegaly [up-to-25% increase in left ventricular (LV mass)] with no significant LV wall thickening. The LV internal diameter was significantly wider (up-to-24% increase at 9-months), when compared to the age-matched WT. In addition, there were significant increases in the end-systolic, end-diastolic volumes and stroke volume, suggesting volume overload. Significant reduction in Global longitudinal strain (GLS) measuring local myofiber contractility of the LV was also detected at 13-months. Similar GLS reduction was also reported in FD patients. Parameters such as ejection fraction, fractional shortening and cardiac output were either only slightly affected or were not different from controls. On the other hand, some of the cardiac findings in G3Stg\/<jats:italic>Gla<\/jats:italic>KO mice were inconsistent with Fabry cardiomyopathy seen in FD patients. This could be potentially an artifact of the Gb3 synthase overexpression under a strong ubiquitous promoter. In conclusion, <jats:italic>Gla<\/jats:italic>KO mouse model presents mild cardiomegaly, mild cardiac dysfunction, but significant cardiac volume overload and functional changes in GLS that can be used as translational biomarkers to determine cardiac efficacy of novel treatment modalities. The level of tissue Gb3 accumulation in G3Stg\/<jats:italic>Gla<\/jats:italic>KO mouse more closely recapitulates the level of substrate accumulation in FD patients and may provide better translatability of the efficacy of new therapeutics in clearing pathological substrates from cardiac tissues. But interpretation of the effect of treatment on cardiac structure and function in this model should be approached with caution.<\/jats:p>","DOI":"10.1371\/journal.pone.0304415","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T20:10:22Z","timestamp":1717186222000},"page":"e0304415","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiac manifestations of Fabry disease in G3Stg\/GlaKO and GlaKO mouse models\u2013Translation to Fabry disease patients"],"prefix":"10.1371","volume":"19","author":[{"given":"Abirami","family":"Kugadas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Artoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5168-7582","authenticated-orcid":true,"given":"Wanida","family":"Ruangsiriluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Boukharov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1613-6370","authenticated-orcid":true,"given":"Rizwana","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Volfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3807-2701","authenticated-orcid":true,"given":"Katayoun","family":"Derakhchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"issue":"3922","key":"pone.0304415.ref001","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry\u2019s disease: alpha-galactosidase deficiency","volume":"167","author":"JA Kint","year":"1970","journal-title":"Science"},{"issue":"5","key":"pone.0304415.ref002","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study","volume":"28","author":"M Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"pone.0304415.ref003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5734\/JGM.2023.20.1.6","article-title":"Fabry disease: current treatment and future perspective","volume":"20","author":"HW Yoo","year":"2023","journal-title":"Journal of Genetic Medicine"},{"issue":"9","key":"pone.0304415.ref004","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"H Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"447","key":"pone.0304415.ref005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1651-2227.2005.tb02103.x","article-title":"Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy","volume":"94","author":"JS Shah","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"pone.0304415.ref006","article-title":"Preliminary results of STAAR, a Phase I\/II study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up.","author":"J Ganesh","year":"2022","journal-title":"Annu Symp Soc Study Inborn Errors Metab (SSIEM)"},{"key":"pone.0304415.ref007","article-title":"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease","author":"JM Jeyakumar","year":"2023","journal-title":"Gene Ther"},{"issue":"3","key":"pone.0304415.ref008","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cjca.2010.12.035","article-title":"Myocardial alterations in the murine model of fabry disease can be reversed by enzyme replacement therapy","volume":"27","author":"PA Rozenfeld","year":"2011","journal-title":"Can J Cardiol"},{"issue":"2","key":"pone.0304415.ref009","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.ASN.0000043901.45141.D4","article-title":"Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis","volume":"14","author":"DT Eitzman","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"pone.0304415.ref010","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1681.2008.04984.x","article-title":"Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect","volume":"35","author":"JL Park","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"5","key":"pone.0304415.ref011","doi-asserted-by":"crossref","first-page":"e33743","DOI":"10.1371\/journal.pone.0033743","article-title":"Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease","volume":"7","author":"A Nguyen Dinh Cat","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"pone.0304415.ref012","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"T Ohshima","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0304415.ref013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BJ20130825","article-title":"A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis","volume":"456","author":"A Taguchi","year":"2013","journal-title":"Biochem J"},{"issue":"8","key":"pone.0304415.ref014","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1096\/fj.201701374R","article-title":"Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice.","volume":"32","author":"H Maruyama","year":"2018","journal-title":"FASEB J"},{"issue":"7","key":"pone.0304415.ref015","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ehjci\/jeaa101","article-title":"The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage","volume":"22","author":"JB Augusto","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"pone.0304415.ref016","doi-asserted-by":"crossref","first-page":"e009430","DOI":"10.1161\/CIRCIMAGING.119.009430","article-title":"Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.","volume":"12","author":"S Nordin","year":"2019","journal-title":"Circ Cardiovasc Imaging."},{"key":"pone.0304415.ref017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcmg.2019.07.020","article-title":"Normal Global Longitudinal Strain: An Individual Patient Meta-Analysis.","volume":"13","author":"N D\u2019Elia","year":"2020","journal-title":"JACC Cardiovasc Imaging."},{"issue":"4","key":"pone.0304415.ref018","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/ehjci\/jeab214","article-title":"Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy","volume":"23","author":"DY Lu","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"pone.0304415.ref019","doi-asserted-by":"crossref","first-page":"107306","DOI":"10.1016\/j.ymgme.2022.107306","article-title":"Cardiac effects of 4D-310 in adults with Fabry disease in a phase 1\/2 clinical trial: Functional, quality of life, and imaging endpoints in patients with 12 months of follow up","volume":"138","author":"R Schiffmann","year":"2023","journal-title":"Molecular Genetics and Metabolism"},{"key":"pone.0304415.ref020","doi-asserted-by":"crossref","first-page":"107034","DOI":"10.1016\/j.ymgme.2022.107034","article-title":"Characterization of the G3Stg\/KO Fabry disease mouse model pathology to improve preclinical to clinical translation","volume":"138","author":"N Boukharov","year":"2023","journal-title":"Molecular Genetics and Metabolism"},{"key":"pone.0304415.ref021","article-title":"Manuscript ID HUM-2023-222. Developing gene therapy for mitigating multisystemic pathology in Fabry disease: proof of concept in an aggravated mouse model","author":"S Yuan","year":"2024","journal-title":"Human Gene Therapy, In Revision"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T20:10:37Z","timestamp":1717186237000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304415"}},"subtitle":[],"editor":[{"given":"Israel","family":"Silman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304415","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}